Hep Talk

Hep Talk by Larry Buhl For MSMs: treatment hope for HCV—and a warning There’s more evidence of the effectiveness of new antiretroviral drugs in treating the...

It's a Hispanic Thing Hep outreach & research are needed for a vulnerable community by Larry Buhl In a presentation at a National Hispanic Medical Association (NHMA)...

With new, game-changing hepatitis C meds available or in the pipeline, an emerging issue is how to find at-risk patients, get them screened and...

After nearly three decades of entrenched opposition to funding programs that allow drug users to obtain free sterile syringes, the U.S. Congress in January...

While federal efforts move forward, hepatitis prevention remains unfunded by Larry Buhl During the seemingly interminable debate over health insurance reform, other health legislation was quietly...

New meds offer hope for interferon-free regimen by Larry Buhl LifeGuide In the past year several protease inhibitors were introduced for chronic hepatitis C, marking a...

Cost of treatment and prevention in the war on viral hepatitis was the overriding theme of the first World Hepatitis Summit, which drew more...

It is well known that people with hepatitis C virus (HCV) are at risk for liver damage, but the results of two new studies...

Hep Talk Hepatitis C Antiviral Telaprevir Moves Closer to Approval by Larry Buhl Researchers in a recent Phase III study are encouraged by the results of a...

Approved by the fda, telaprevir and boceprevir usher in a new era of treatment by Larry Buhl The first breakthrough treatments for liver disease to...